

## Special Issue

# Glioma Diagnostics in the Genetics Era

### Message from the Guest Editor

Integrating genetics into the diagnostic work-up of cancer has become commonplace, and indeed necessary, across many oncology fields. However, the rapid expansion of genetic methods and new discoveries exceeded the speed at which new diagnostic guidelines could be published. As a result, this spurred a period of uncertainty as to how best to diagnose a tumor in an accurate, timely, and cost-effective manner.

An integrated approach leveraging the clinical presentation, morphological features, and genetic results likely reflects the most logical solution. However, this integrated approach has, at this time, not been formalized. Here, we'll provide editorials from stakeholders of different elements of this integrated approach: clinical oncologists, neuropathologists, clinical geneticists, and laboratorians. We'll provide examples of the important blind-spots each strategy can address. In this respect, we hope to continue the on-going dialogue of how best to integrate the plethora of data now available to clinicians to provide the most accurate diagnosis and care to our patients.

---

### Guest Editor

Dr. Scott Ryall

1. Brigham and Women's Hospital, Boston, MA 02115, USA
2. Harvard Medical School, Boston, MA 02115, USA

---

### Deadline for manuscript submissions

closed (25 September 2025)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/221011](https://mdpi.com/si/221011)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))